Exelixis Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hi, everyone. I'm Jennifer Kim, a large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Exelixis. Exelixis is an oncology-focused biotech company with 4 commercial products, including their flagship product, cabozantinib, and a novel pipeline of cancer therapies.
Today, we're very excited to have with us the President and CEO, Michael Morrissey, to discuss the company's pipeline and the market opportunity for its products. Michael, thanks so much for taking the time today.
You bet. Great to be here. Thanks for that great intro, and happy to have some time with you today. Before I begin, I'll just remind everybody that I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |